Displaying publications 161 - 180 of 55979 in total

Abstract:
Sort:
  1. Mitchell PJ, Chan DD, Lee JK, Tabu I, Alpuerto BB
    Best Pract Res Clin Rheumatol, 2022 Sep;36(3):101777.
    PMID: 36089481 DOI: 10.1016/j.berh.2022.101777
    The current burden of fragility fractures is enormous, and it is set to increase rapidly in the coming decades as humankind enters a new demographic era. The purpose of this review is to consider, in different settings: • The human and economic toll of fragility fractures. • Risk factors for fragility fractures. • Current acute management of fragility fractures. • Current care gaps in both secondary and primary fracture prevention. A summary of global, regional, and national initiatives to improve the quality of care is provided, in addition to proposals for the research agenda. Systematic approaches to improve the acute care, rehabilitation and prevention of fragility fractures need to be developed and implemented rapidly and at scale in high-, middle- and low-income countries throughout the world. This must be an essential component of our response to the ageing of the global population during the remainder of the current United Nations - World Health Organization "Decade of Healthy Ageing".
    Matched MeSH terms: Humans
  2. Khan DM, Yahya N, Kamel N, Faye I
    Comput Methods Programs Biomed, 2023 Jan;228:107242.
    PMID: 36423484 DOI: 10.1016/j.cmpb.2022.107242
    BACKGROUND AND OBJECTIVE: Brain connectivity plays a pivotal role in understanding the brain's information processing functions by providing various details including magnitude, direction, and temporal dynamics of inter-neuron connections. While the connectivity may be classified as structural, functional and causal, a complete in-vivo directional analysis is guaranteed by the latter and is referred to as Effective Connectivity (EC). Two most widely used EC techniques are Directed Transfer Function (DTF) and Partial Directed Coherence (PDC) which are based on multivariate autoregressive models. The drawbacks of these techniques include poor frequency resolution and the requirement for experimental approach to determine signal normalization and thresholding techniques in identifying significant connectivities between multivariate sources.

    METHODS: In this study, the drawbacks of DTF and PDC are addressed by proposing a novel technique, termed as Efficient Effective Connectivity (EEC), for the estimation of EC between multivariate sources using AR spectral estimation and Granger causality principle. In EEC, a linear predictive filter with AR coefficients obtained via multivariate EEG is used for signal prediction. This leads to the estimation of full-length signals which are then transformed into frequency domain by using Burg spectral estimation method. Furthermore, the newly proposed normalization method addressed the effect on each source in EEC using the sum of maximum connectivity values over the entire frequency range. Lastly, the proposed dynamic thresholding works by subtracting the first moment of causal effects of all the sources on one source from individual connections present for that source.

    RESULTS: The proposed method is evaluated using synthetic and real resting-state EEG of 46 healthy controls. A 3D-Convolutional Neural Network is trained and tested using the PDC and EEC samples. The result indicates that compared to PDC, EEC improves the EEG eye-state classification accuracy, sensitivity and specificity by 5.57%, 3.15% and 8.74%, respectively.

    CONCLUSION: Correct identification of all connections in synthetic data and improved resting-state classification performance using EEC proved that EEC gives better estimation of directed causality and indicates that it can be used for reliable understanding of brain mechanisms. Conclusively, the proposed technique may open up new research dimensions for clinical diagnosis of mental disorders.

    Matched MeSH terms: Humans
  3. Keusch GT, Lam SK, Mackenzie JS, Saif L, Turner M
    Lancet, 2021 Oct 16;398(10309):1404-1405.
    PMID: 34543607 DOI: 10.1016/S0140-6736(21)02013-4
    Matched MeSH terms: Humans
  4. Ch'ng CC, Ong LM, Wong KM
    Med J Malaysia, 2022 Nov;77(6):768-770.
    PMID: 36448398
    The SARS-Cov-2 (COVID-19) vaccination began in Malaysia in March 2021 among frontliners and healthcare workers. Everyone at our hospital received the tozinameran (BNT162b2) Messenger RNA COVID-19 vaccine. Although hypertension has not been mentioned explicitly as an adverse event, concerns were raised after some healthcare staff observed an increase in their blood pressures. In response to that, the hospital began collecting vital signs during second-dose appointments. Vital signs were measured before, immediately after and 15-30 minutes postvaccination. We report our findings from the institution-wide effort to monitor changes in blood pressure among its staff and respond to any possible unwanted events.
    Matched MeSH terms: Humans
  5. Ooi KX, Poo CL, Subramaniam M, Cordell GA, Lim YM
    Phytomedicine, 2023 Feb;110:154631.
    PMID: 36621168 DOI: 10.1016/j.phymed.2022.154631
    BACKGROUND: Natural products have long been regarded as a source of anticancer compounds with low toxicity. Evidence revealed that maslinic acid (MA), a widely distributed pentacyclic triterpene in common foodstuffs, exhibited pronounced inhibitory effects against various cancer cell lines. Most cancer cells thrive by acquiring cancer hallmarks, as coined by Hanahan and Weinberg in 2000 and 2011.

    PURPOSE: This represents the first systematic review concerning the anticancer properties of MA as these cancer hallmarks are targeted. It aims to summarize the antineoplastic activities of MA, discuss the diverse mechanisms of action based on the effects of MA exerted on each hallmark.

    METHODS: A comprehensive literature search was conducted using the search terms "maslinic," "cancer," "tumor," and "neoplasm," to retrieve articles from the databases MEDLINE, EMBASE, Web of Science, and Scopus published up to September 2022. Study selection was conducted by three reviewers independently from title and abstract screening until full-text evaluation. Data extraction was done by one reviewer and counterchecked by the second reviewer.

    RESULTS: Of the 330 articles assessed, 40 papers met the inclusion criteria and revealed that MA inhibited 16 different cancer cell types. MA impacted every cancer hallmark by targeting multiple pathways.

    CONCLUSION: This review provides insights regarding the inhibitory effects of MA against various cancers and its remarkable biological properties as a pleiotropic bioactive compound, which encourage further investigations.

    Matched MeSH terms: Humans
  6. Chew BH, Mohd-Yusof BN, Lai PSM, Khunti K
    Endocrinol Metab (Seoul), 2023 Feb;38(1):34-42.
    PMID: 36792353 DOI: 10.3803/EnM.2022.1649
    The ultimate purpose of diabetes care is achieving the outcomes that patients regard as important throughout the life course. Despite advances in pharmaceuticals, nutraceuticals, psychoeducational programs, information technologies, and digital health, the levels of treatment target achievement in people with diabetes mellitus (DM) have remained suboptimal. This clinical care of people with DM is highly challenging, complex, costly, and confounded for patients, physicians, and healthcare systems. One key underlying problem is clinical inertia in general and therapeutic inertia (TI) in particular. TI refers to healthcare providers' failure to modify therapy appropriately when treatment goals are not met. TI therefore relates to the prescribing decisions made by healthcare professionals, such as doctors, nurses, and pharmacists. The known causes of TI include factors at the level of the physician (50%), patient (30%), and health system (20%). Although TI is often multifactorial, the literature suggests that 28% of strategies are targeted at multiple levels of causes, 38% at the patient level, 26% at the healthcare professional level, and only 8% at the healthcare system level. The most effective interventions against TI are shorter intervals until revisit appointments and empowering nurses, diabetes educators, and pharmacists to review treatments and modify prescriptions.
    Matched MeSH terms: Humans
  7. Kow CS, Ramachandram DS, Hasan SS
    J Gen Intern Med, 2023 Mar;38(4):1077.
    PMID: 36414801 DOI: 10.1007/s11606-022-07964-w
    Matched MeSH terms: Humans
  8. Hanbali L, Lehtimaki S, Hannon E, McNab C, Schwalbe N
    Lancet, 2023 Feb 18;401(10376):553.
    PMID: 36736333 DOI: 10.1016/S0140-6736(23)00126-5
    Matched MeSH terms: Humans
  9. Loh MKA, Siew ZY, Leong PP, Koh RY, Chye SM, Wong ST, et al.
    Biomed Environ Sci, 2023 Sep 20;36(9):886-891.
    PMID: 37803902 DOI: 10.3967/bes2023.114
    Matched MeSH terms: Humans
  10. Posadino AM, Giordo R, Pintus G, Mohammed SA, Orhan IE, Fokou PVT, et al.
    Biomed Pharmacother, 2023 Jul;163:114866.
    PMID: 37182516 DOI: 10.1016/j.biopha.2023.114866
    Artemisinin (ART) is a bioactive compound isolated from the plant Artemisia annua and has been traditionally used to treat conditions such as malaria, cancer, viral infections, bacterial infections, and some cardiovascular diseases, especially in Asia, North America, Europe and other parts of the world. This comprehensive review aims to update the biomedical potential of ART and its derivatives for treating human diseases highlighting its pharmacokinetic and pharmacological properties based on the results of experimental pharmacological studies in vitro and in vivo. Cellular and molecular mechanisms of action, tested doses and toxic effects of artemisinin were also described. The analysis of data based on an up-to-date literature search showed that ART and its derivatives display anticancer effects along with a wide range of pharmacological activities such as antibacterial, antiviral, antimalarial, antioxidant and cardioprotective effects. These compounds have great potential for discovering new drugs used as adjunctive therapies in cancer and various other diseases. Detailed translational and experimental studies are however needed to fully understand the pharmacological effects of these compounds.
    Matched MeSH terms: Humans
  11. Pironi L, Jezerski D, Sobocki J, Lal S, Vanuytsel T, Theilla M, et al.
    Clin Nutr ESPEN, 2023 Jun;55:212-220.
    PMID: 37202049 DOI: 10.1016/j.clnesp.2023.03.008
    BACKGROUND AND AIMS: To investigate the incidence and the severity of COVID-19 infection in patients enrolled in the database for home parenteral nutrition (HPN) for chronic intestinal failure (CIF) of the European Society for Clinical Nutrition and Metabolism (ESPEN).

    METHODS: Period of observation: March 1st, 2020 March 1st, 2021.

    INCLUSION CRITERIA: patients included in the database since 2015 and still receiving HPN on March 1st, 2020 as well as new patients included in the database during the period of observation. Data related to the previous 12 months and recorded on March 1st 2021: 1) occurrence of COVID-19 infection since the beginning of the pandemic (yes, no, unknown); 2) infection severity (asymptomatic; mild, no-hospitalization; moderate, hospitalization no-ICU; severe, hospitalization in ICU); 3) vaccinated against COVID-19 (yes, no, unknown); 4) patient outcome on March 1st 2021: still on HPN, weaned off HPN, deceased, lost to follow up.

    RESULTS: Sixty-eight centres from 23 countries included 4680 patients. Data on COVID-19 were available for 55.1% of patients. The cumulative incidence of infection was 9.6% in the total group and ranged from 0% to 21.9% in the cohorts of individual countries. Infection severity was reported as: asymptomatic 26.7%, mild 32.0%, moderate 36.0%, severe 5.3%. Vaccination status was unknown in 62.0% of patients, non-vaccinated 25.2%, vaccinated 12.8%. Patient outcome was reported as: still on HPN 78.6%, weaned off HPN 10.6%, deceased 9.7%, lost to follow up 1.1%. A higher incidence of infection (p = 0.04), greater severity of infection (p 

    Matched MeSH terms: Humans
  12. Finsterer J
    Med J Malaysia, 2023 Mar;78(2):260-261.
    PMID: 36988540
    No abstract available.
    Matched MeSH terms: Humans
  13. de Souza AC, Lioutas V, Sebastian I, Asyraf W, Amaya P, Rocha E, et al.
    Stroke, 2023 Aug;54(8):e399-e402.
    PMID: 37264914 DOI: 10.1161/STROKEAHA.122.038459
    Matched MeSH terms: Humans
  14. Kow CS, Ramachandram DS, Hasan SS
    J Med Virol, 2022 May;94(5):2269-2274.
    PMID: 34978339 DOI: 10.1002/jmv.27568
    We aimed to perform meta-analyses to summarize the overall effectiveness of the mRNA-1273 vaccine against COVID-19 caused by the Delta variant from real-world studies. A systematic literature search with no language restriction was performed in electronic databases to identify eligible observational studies that reported the effectiveness of the mRNA-1273 vaccine to prevent reverse transcription-polymerase chain reaction (RT-PCR) confirmed COVID-19 caused by Delta variant of SARS-CoV-2 (B.1.617.2). A random-effects meta-analysis model was used to estimate the pooled odds ratio (OR) at a 95% confidence interval (CI), and the vaccine effectiveness was indicated as (pooled OR - 1)/OR. Five studies were included for this systematic review and meta-analysis. The meta-analysis revealed that the administration of mRNA-1273 vaccine protected against RT-PCR confirmed COVID-19 caused by Delta variant ≥21 days post first dose, with pooled vaccine effectiveness of 66% (95% CI: 65%-67%), as well as ≥14 days after the second dose, with pooled vaccine effectiveness of 91% (95% CI: 84%-95%). In conclusion, the mRNA-1273 vaccine offers a substantial protection rate against RT-PCR confirmed COVID-19 caused by the Delta variant upon full vaccination, although with slightly reduced effectiveness relative to other strains of SARS-CoV-2.
    Matched MeSH terms: Humans
  15. Salari N, Morddarvanjoghi F, Abdolmaleki A, Rasoulpoor S, Khaleghi AA, Hezarkhani LA, et al.
    BMC Cardiovasc Disord, 2023 Apr 22;23(1):206.
    PMID: 37087452 DOI: 10.1186/s12872-023-03231-w
    BACKGROUND: Myocardial infarction (MI) is one of the life-threatening coronary-associated pathologies characterized by sudden cardiac death. The provision of complete insight into MI complications along with designing a preventive program against MI seems necessary.

    METHODS: Various databases (PubMed, Web of Science, ScienceDirect, Scopus, Embase, and Google scholar search engine) were hired for comprehensive searching. The keywords of "Prevalence", "Outbreak", "Burden", "Myocardial Infarction", "Myocardial Infarct", and "Heart Attack" were hired with no time/language restrictions. Collected data were imported into the information management software (EndNote v.8x). Also, citations of all relevant articles were screened manually. The search was updated on 2022.9.13 prior to the publication.

    RESULTS: Twenty-two eligible studies with a sample size of 2,982,6717 individuals ( 60 years), this value was detected at 9.5%.

    CONCLUSION: Due to the accelerated rate of MI prevalence in older ages, precise attention by patients regarding the complications of MI seems critical. Thus, determination of preventive planning along with the application of safe treatment methods is critical.

    Matched MeSH terms: Humans
  16. Muhd Besari A, Lim JA, Vellaichamy PT, Hussain FA, Kamaludin Z, Nor M
    Postgrad Med J, 2022 Mar 01;98(e2):e70.
    PMID: 37066525 DOI: 10.1136/postgradmedj-2021-140778
    Matched MeSH terms: Humans
  17. Yam MF, Loh HW
    Forensic Sci Med Pathol, 2022 Dec;18(4):557-558.
    PMID: 36048324 DOI: 10.1007/s12024-022-00513-1
    Matched MeSH terms: Humans
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links